A simple, precise and accurate RP-HPLC 
Introduction
Analytical chemistry is often described as the area of chemistry responsible for characterizing the composition of matter, both qualitatively and quantitatively [1] , for analyzing the drug sample in bulk, pharmaceutical formulations and biological fluids, many analytical techniques are used [2] . The instrumental method like High Performance Liquid Chromatography (HPLC) was derive from the classical column chromatography and, is widely used tool of analytical chemistry now a day [3] .
Ketorolac is a pyrrolizine carboxylic acid derivative structurally related to indomethacin and chemically it is designated as 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. It is an NSAID and is used principally for its analgesic activity. Ketorolac is a Nonsteroidal anti-inflammatory drug (NSAID) chemically related to indomethacin and tolmetin. Ketorolac is a racemic mixture of [-] S-and [+]R-enantiomeric forms, with the S-form having analgesic activity. Its anti-inflammatory effects are believed to be due to inhibition of both cylooxygenase-1 (COX-1) and cylooxygenase-2 (COX-2) which leads to the inhibition of prostaglandin synthesis leading to decreased formation of precursors of prostaglandins and thromboxanes from arachidonic acid. The resultant reduction in prostaglandin synthesis and activity may be at least partially responsible for many of the adverse, as well as the therapeutic, effects of these medications. Febuxostat is a non-purine selective inhibitor of xanthine oxidase. It works by non-competitively blocking the molybdenum pterin center which is the active site on xanthine oxidase. Xanthine oxidase is needed to successively oxidize both hypoxanthine and xanthine to uric acid. Hence, Febuxostat inhibits xanthine oxidase, therefore reducing production of uric acid. Febuxostat inhibits both oxidized as well as reduced form of xanthine oxidase because of which Febuxostat cannot be easily displaced from the molybdenum pterin site [4] [5] [6] . A survey of literature [4] [5] [6] [7] [8] [9] [10] reveals that, other reported methods for Febuxostat include Spectrophotometry, HPLC and LC-MS in varied Matrices like formulations and biological fluids. As highlighted earlier, the use of the above drug has become very wide spread. It is however, surprising to note that, only few methods are only available at present for the estimation of the drug in pharmaceutical formulations. The present project seeks to bridge this gap by developing a novel method.
Materials and Methods

Instrumentation and analytical conditions
Quantitative HPLC was performed on a Liquid Chromatography of Waters separation 2996, PDA detector module equipped with automatic injector with injection volume 20 µl, and 2693 pump. A Novapak-RP-C18 column (150x3.9 mm i.d; particle size 4 µm) was used. The HPLC system was equipped with Empower Software. Chromatographic conditions were tabulated in the Table 1 . 
Observation
Theoretical plates are less, peak shape is not good, and fronting is there in graph and plate count is less than 2000.
Trail 2: Febuxostat and Ketorolac
Mobile Phase
Buffer and Acetonitrile were mixed in the ratio of 50:50 v/v and sonicated to degas. 
Observation
The retention time is more, and asymmetry is high, asymmetry is more than limit sound noise ratio (S/N) is not meeting the limits.
Trail 3: Febuxostat and Ketorolac
Mobile Phase
Acetate Buffer and Water HPLC grade were mixed in the ratio of 50:50 v/v and sonicated to degas. 
Chromatographic Conditions
Observation
Retention time is high, and asymmetry is high 
Mobile Phase
Buffer and Methanol were mixed in the ratio of 40:60 v/v and sonicated to degas.
Preparation of working standard solution
Aliquots ranging from 0.5 ml to 1.5 ml of KET and 0.2 ml to 0.6 ml were taken from working stock solution (100 µg/ml-KET, 1000 µg/ml-FEB) and diluted to 10ml with mobile phase to give final concentration of 5-15 μg/ml of ketorolac and 20-60 μg/ml of Febuxostat.
Preparation of sample drug solution for pharmaceutical formulations
The marketed formulations containing 10 mg of Ketorolac and 40 mg of Febuxostat was taken. From the above solution subsequent concentrations of 5-15 μg/ml and 20 to 60 µg/ml were prepared with mobile phase, sonicated and filtered through 0.45 μ membrane filtered
Procedure
Initially the mobile phase was pumped for about 30 min to saturate the column thereby to set the baseline corrected. Then 20 µl of the standard and sample solutions were injected separately. A quantitative determination of the active ingredients was made by comparison of the peak area of the sample injection with the corresponding peak area of the standard injection. The amount of Febuxostat and Ketorolac present in the sample was calculated through the standard calibration curve.
Procedure for calibration curve
The contents of the mobile phase were filtered before use through 0.45 µ membrane and pumped from the respective solvent reservoirs to the column at a specified flow rate. Prior to injection of the drug solutions, the column was equilibrated for at least 30 min with the mobile phase flowing through the system. The chromatographic separation was achieved using a mobile phase consisting of Buffer and Methanol at 40:60 v/v the eluent was monitored using UV detector at a wavelength of 321 nm. The column was maintained an ambient temperature (250c) and an injection volume of 20 µl of each of standard and sample solutions were injected into the HPLC system to get the chromatograms. The retention time, peak area of drug was recorded graph was plotted by taking concentration of the drug on x-axis and peak area on y-axis. 
Results and Discussion
Method validation parameters Specificity
The system suitability for specificity was carried out to determine whether there is any interference of any 
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Linearity
The linearity of an analytical method is its ability to elicit test results that are directly or by a well-defined mathematical transformation, proportional to the concentration of analyte in samples within a given range. Serial dilutions of Febuxostat and Ketorolac (5-15 µg/ml and 20-60 µg/ml) were injected into the column and detected at a wavelength set at 321 nm. The calibration curve was obtained by plotting the concentration vs. peak area [10] . 
Acceptance criteria
Correlation Coefficient should be not less than 0.999. 8% of RSD for level 1 and level 6 should be not more than 2.0%.
Recovery Studies
Recovery studies were conducted by analyzing the formulations in the first instance for the active ingredients in the concentration of 50% of the working standard solution, 100% of the working standard solution (40 µg/ml of Febuxostat and 10 µg/ml of Ketorolac) and 150% of the working standard solution by the proposed method. Each concentration was injected three times and the peak areas were recorded. The known amount of the pure drug of the working standard solution contains was 
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Range
Based on precision, linearity and accuracy data it can be concluded that the assay method is precise, linear and accurate in the range of 5-55 µg/ml and 20-60 µg/ml for Febuxostat and Ketorolac respectively. 
Accuracy
To determine the accuracy of the proposed method, different amounts of bulk sample of Febuxostat and Ketorolac within linearity limits was taken and analyzed by the proposed method.
Calculations
Where, At=Average area due to Formulation peak in sample preparation As=Average area due to peak in the Standard preparation Ws=Weight of the working standard Wt Weight of the sample Formulation P=Potency of the working standard Avg.Wt=Average Weight.
Precision
The precision was repeated with the formulated sample for the same concentrations by injecting the working sample solutions containing 40 µg/ml of Febuxostat and 10 µg/ml of Ketorolac. The sample Febuxostat and Ketorolac was processed six times for the response of peak area. The % Relative Standard Deviation (RSD), were calculated and presented in Tables: 6 & 7 respectively.
Acceptance criteria
The individual assays of Febuxostat and Ketorolac should be not less than 98% and not more than 102% and %RSD of assay should be NMT 2.0% by both analysts. To determine the accuracy of the proposed method, different amounts of bulk sample of Ketorolac within linearity limits was taken and analyzed by the proposed method.
Assay Results: (Ketorolac)
Acceptance criteria
The mean % recovery of the Febuxostat and Ketorolac at each level should be not less than 95.0% and not more than 105.0%. 
Robustness
Effect of variation of flow rate
A study was conducted to determine the effect of variation in flow rate. Standard solution prepared as per the test method was injected into the HPLC system using flow rates, 1.0 ml/min and 1.2 ml/min. The system suitability parameters were evaluated and found to be within the limits for 1.0 ml/min and 1.2 ml/min flow.
Febuxostat (FEB) and ketorolac (KET) was resolved from all other peaks and the retention times were comparable with those obtained for mobile phase having flow rates 1.0 ml/min.
Acceptance criteria
The Tailing Factor of FEB & KET standards should be NMT 2.0 for Variation in Flow. 
Limit of Detection (LOD) and Limit of Quantification
The detection limit of the method was investigated by injecting standard solutions into the HPLC column. By using the signal-to-noise (S/N) method, the peak-to-peak noise around the analyte retention time is measured. Subsequently, the concentration of the analyte which would yield a signal equal to certain value of noise to signal ratio was also estimated. A signal-to-noise ratio (S/N) of 3 was generally accepted for estimating LOD and signal-to-noise (S/N) ratio of 10 was used for estimating LOQ.
The LOD was found to be 0.04 µg/ml for Febuxostat and 0.12 µg/ml for Ketorolac. The LOQ was found to be 0.16 µg/ml for Febuxostat and 0.42 µg/ml for Ketorolac.
Summary and Conclusion
There are only few reported methods on the RP-HPLC determination of Febuxostat and Ketorolac in Tablet dosage form in the literature prior to the commencement of this work. The author has developed a sensitive, accurate and precise RP-HPLC procedure for the estimation of Febuxostat and Ketorolac in bulk drug and also in pharmaceutical formulations.
From the typical chromatogram of Febuxostat and Ketorolac, it was found that the retention times were Thus, the present procedures constitute the RP-HPLC method with good precision, accuracy and sensitivity for the simultaneous estimation of Febuxostat and Ketorolac in pure stage and in pharmaceutical formulations.
